NCT Number: NCT04038502
Phase: Phase 2
Trial Summary: This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): VA Office of Research and Development
Acronym: COBRA
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives